Dnajc22 Inhibitors constitute a distinctive class of chemical compounds that hold the capacity to modulate the activity of the DNJC22 protein, a member of the DnaJ/Hsp40 family. This class of proteins is recognized for its pivotal role in a multitude of cellular processes, primarily centered around protein folding, chaperone-assisted protein quality control, and intracellular trafficking. The DNJC22 protein, in particular, operates as an essential co-chaperone, facilitating the proper folding of client proteins and assisting in their productive integration into cellular pathways. Inhibitors tailored to target DNJC22 exhibit a specific mode of action, which usually involves the binding to discrete binding sites or functional domains within the protein's structure. By engaging with these specific regions, these inhibitors can effectively influence the conformational dynamics of the protein or hamper its interactions with other cellular components. Through these actions, the inhibitors have the potential to disrupt the intricate network of processes DNJC22 participates in.
As researchers delve into the exploration of DNJC22 inhibitors, the primary objective revolves around deciphering the precise implications of manipulating the protein's activity. By utilizing these inhibitors as molecular tools, scientists can illuminate the protein's functional relevance across diverse cellular pathways. Furthermore, this approach might yield insights into the underlying mechanisms of protein folding and quality control, shedding light on broader cellular processes. Instead, the focus rests on deciphering the intricate cellular ballet orchestrated by DNJC22 and its implications for cellular homeostasis. This fundamental research holds the potential to unravel new facets of cellular biology, thereby contributing to a deeper understanding of the complexity that underlies cellular function. As scientific understanding evolves, the pursuit of DNJC22 inhibitors continues to shape the landscape of molecular and cellular research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Binds to the ATP-binding site of specific tyrosine kinases, inhibiting their activity and interrupting cell signaling pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Blocks the proteasome, leading to accumulation of proteins and triggering cell death pathways. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Inhibits histone deacetylases, leading to altered gene expression and potential anti-cancer effects. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
Blocks HMG-CoA reductase, lowering blood cholesterol levels. | ||||||
Ritonavir | 155213-67-5 | sc-208310 | 10 mg | $124.00 | 7 | |
Inhibits the HIV protease enzyme, preventing viral replication. | ||||||
Donepezil | 120014-06-4 | sc-279006 | 10 mg | $74.00 | 3 | |
Blocks acetylcholinesterase, improving cognitive function in Alzheimer's disease. | ||||||
Acetazolamide | 59-66-5 | sc-214461 sc-214461A sc-214461B sc-214461C sc-214461D sc-214461E sc-214461F | 10 g 25 g 100 g 250 g 500 g 1 kg 2 kg | $81.00 $177.00 $434.00 $541.00 $883.00 $1479.00 $2244.00 | 1 | |
Inhibits carbonic anhydrase enzyme, used for glaucoma and altitude sickness. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $92.00 | 1 | |
Inhibits aromatase enzyme, used in for hormone receptor-positive breast cancer. | ||||||
Oseltamivir | 196618-13-0 | sc-507283 | 100 g | $324.00 | ||
Inhibits influenza neuraminidase enzyme, preventing viral particle release. | ||||||
3′-Azido-3′-deoxythymidine | 30516-87-1 | sc-203319 | 10 mg | $61.00 | 2 | |
Inhibits HIV reverse transcriptase, used in antiretroviral therap | ||||||